hpv prostatitis

Painful, Slow & Stinging Urination?
Watch This Video Before You Buy Anything

[mage lang="" source="flickr"]hpv prostatitis[/mage]

Innovations for the diagnosis of cancer: Advances in technology, opportunities for growth and future market

The major events is likely that both the market for IVD imaging modalities such as CT, with the emphasis in the approach to medicine Personalized where demand will come from doctors, patients and taxpayers – who want treatments more effective and efficient.

This report analyzes the most Recent innovations in the diagnosis of cancer and identify new technologies and trends of interest, ranging from body image and cytologic diagnosis molecular and pharmacogenomics. The report also identifies the main challenges companies innovative diagnostics.

Key Features this report

• Analysis of recent innovations in diagnostic imaging in the field of oncology, which includes imaging Magnetic resonance imaging (MRI), X-rays, computed tomography (CT), ultrasound, positron emission tomography (PET), positron single photon emission (SPECT) and flow cytometry.
• Analyze the latest innovations in diagnostic molecular biology and its impact on the diagnostics market. The report covers the technology, including fluorescent in situ hybridization (FISH) chain reaction (PCR), HPV testing, immunoassays biomarkers and chips and comparative genomic hybridization (CGH).
• Analyze the latest developments in pharmacogenomics and covers the main applications for cancer of the family, breast cancer, colon cancer and lung cancer. In addition, the report provides an overview of the environment and property settlement Intellectual genetic testing based.
• Styles key business challenges for innovative diagnostics, including the impact the recession, reimbursement, regulatory changes, pharmacoeconomics and the relationship between industry and universities.
Report includes detailed case studies on the potential of available technologies in key areas of the United Nations-met need that cancers ovarian and colorectal cancers.

The main advantages of this report

• Understanding the latest innovations in market of oncology diagnostics in central areas – diagnostic imaging, molecular diagnostics and pharmacogenetics. This includes market information and analysis of scientific literature to identify what is truly innovative.
• Identify key areas of unmet need in the market of oncology diagnostic and know what products are the greatest potential in the next decade.
• Understand what are the greatest challenges for the diagnosis of cancer and what are the best strategies for overcoming these obstacles.
• Competitor analysis and what companies are leading the track in terms of innovation, partnerships and recent diagnosis of the company.
• Business Insights has identified five key areas innovation in diagnostics markets, use this guide to help the company strategy.

The main findings this report

Molecular diagnostics and biomarkers are key diagnostic oncology market.

Despite the economic downturn deep, the R & D were maintained for businesses in oncology diagnosis. However, mergers and acquisitions has been affected by the value of transactions in 2009, well below the record year of 2007.

Associations between pharmaceutical companies and diagnostic companies represent the future of the industry and the number of corporate deals has steadily increased in recent years.

Virtual colonoscopy – Using computed tomography to create an image of the colon – is becoming increasingly accepted alternative invasive colonoscopy screening colorectal cancer in high risk groups and the general population. This presents a considerable market opportunity.

Interesting research is conducted in both ovarian cancer and cancer of the prostate, which could affect large market. In particular, firms are looking for validation of new biomarkers to create more precise testing.

The main issues addressed in this report

What is the potential market for in vitro diagnostic products?
What are the market forecasts for the diagnosis in oncology?
What are the main innovations diagnostic tests and imaging?
What are the main areas of unmet need in cancer diagnosis?
What are the most promising areas technology for diagnosis in oncology, and whose businesses exploit this?
What Major trends will impact the market long term?
How large pharmaceutical companies to take full advantage of the possibility of diagnosing cancer of the sector?

Abbott Diagnostics
Affymetrix
Beckman Coulter
Beckton Dickinson
Bio-Rad
Gen-Probe
Johnson & Johnson
Luminex
Nanogen
Roche Diagnostics
Siemens
Sysmex

Contents:

Innovations in cancer diagnostics
Executive Summary 10
Setting the scene 10
Innovations in diagnostic imaging 11
Innovations in molecular diagnostics 12
Innovations in Pharmacogenomics 13
Challenges oncology diagnosis 14
Competitive Landscape 15
Chapter 1 Setting the Scene 18
Abstract 18
Introduction 19
Facts about cancer, current and projected 19
History of 23 cancer diagnoses
The elements of a cancer diagnosis 26
Pathology 27
28 Market oncology diagnostic
Chapter 2 Innovations in diagnostic imaging 34
Summary 34
Introduction 35
Council of 35 images
35 Presentation
38 X-ray
Breast Cancer 38
CT 40
Lung Cancer 40
40 colon
Other 42
44 Ultrasonic
Resonance imaging Magnetic 44
Nuclear Medicine – PET and SPECT 45
Case Study 47
47 hyperimages
Cytology 47
47 Overview
Cytometry Flow 48
Case study 49
49 CellSearch
Review of 50 cervical
Chromosome 52
Chapter 3 Innovations in the diagnosis Molecular 56
Summary 56
Introduction 57
DNA, genes and chromosomes 59
Fluorescent in situ hybridization (FISH) 59
PCR and 60 variants
Case Study 61
HPV testing 61
62 immunoassays and biomarker
Study of 66 cases
ovarian cancer 66
68 PSA tests
areas Search Other 70
Epigenomics 71
72 Microarrays
comparative genomic hybridization (CGH) 73
Case Study 74
Almac 74
74 DiaGenic
List of 74 clinical applications of molecular diagnostics
BCR-ABL 74
75 LOH
MSI 75
Chapter 4 Innovations in pharmacogenomics 78
Summary 78
Introduction 79
79 familial cancer
Breast cancer 80
Colon cancer 81
81 melanoma
Case Study 82
82 IP challenge
The answer 83 treatments
Cytochrome P450 86 variants
86 Overexpression of HER2
The FDA, EMEA and labeling PGX 88
Case Study 89
TheraScreen 89 KRAS
BioTheranostics: 89 breast cancer
Clarient: 90 breast cancer
Marker validation of erlotinib in 90 lung
Companion Diagnostics 91
Chapter 5 challenges in cancer diagnosis 94
Summary 94
Introduction 95
97 Repayment of funds
Patients enrolled = 98 decisions
Regulation 99
101 Medical
Emerging markets 104
Partnerships pharmaceutical companies and academia 105
Research and development 106
Mergers and Acquisitions 109
Chapter 6 competitive environment 112
Abstract 112
Introduction 113
113 Abbot Diagnostics
114 Affymetrix
Beckman Coulter 116
Becton Dickinson 117
119 Bio-Rad Laboratories
Gen-Probe 120
Johnson & Johnson (J & J) 121
Ortho Clinical Diagnostics 121
Luminex 121
Tm Bioscience 122
Nanogen 122
Roche Diagnostics 123
126 Health Diagnostics Siemens
126 Sysmex
future prospects in diagnostic oncology market 127
Science 127
Infrastructure 128
130 Innovation adoption
131 Companion diagnostics
Chapter 7 Appendix 135
135 Glossary
138 Index
LOF
Figure 1.1: The path of new cancer sites, USA 2009 22
Figure 1.2: The path of the new sites of cancer in developing countries, 2007 23
Figure 1.3: Information Required by the oncologist before and after diagnosis 27
Figure 1.4: Diagnostic Oncology forecast ($ m), 2007-14 30
Figure 2.5: Example 3D imaging using tomosynthesis 39
Figure 2.6: Number of TB in the United States, 1995-2008 43
Figure 2.7: Women mammography (%) United States, 2004 * 45
Figure 2.8: Global Market Forecast flow cytometry ($ m) of 2008-14 48
Figure 3.9: Market Forecast IV diagnostic (in million dollars), 2007-2014) 58
Figure 3.10: The use of biomarkers 63
Figure 3.11: Barriers to Development biomarkers 64
Figure 3.12: The United States 5-year survival (%) for ovarian cancer at diagnosis 67
Figure 4.13: Myriad: Molecular Diagnostics Sales ($ m), 2005-09 83
Figure 4.14: Number of biological products regulated by the REDC, with existing information PGX 85
Figure 4.15: Cost treatment with Herceptin ($) Per patient compared to HER2 status 87
Figure 5.16: Reduction of the S & P Global Sector (%) 12 months to 96 December 2008
Figure 5.17: IV diagnostic classification of risk based on 100
Figure 5.18: The FDA validated markers for the therapeutic, September 2009 102
Figure 5.19: Roche Diagnostics regional sales (CHF million), 2008 105
Figure 5.20: Increase in the diagnosis leading R & D (%) Year 2008 107
List of Tables
Table 1.1: WHO estimates of cancer mortality by region (000), 2008-30 21
Table 1.2: Screening of in vitro diagnostic market ($ millions), 2008-14 29
Table 2.3: Overview of imaging systems 37
Table Listing 2.4: reduction of mortality (%) attributed to screening by FOBT, 1985-1996 41
Organizations Table 2.5: Data from 44 clinical studies of radiation
Table 3.6: Many cancer biomarkers research 65
Table 3.7: The market potential for cancer tests 72 specialties Epigenomics
Table 4.8: Missing / incomplete efficiency (%) of 84 drugs by therapeutic class
Table 5.9: Key M & A in the diagnostics industry ($ M), 2009 109
Business Table 6.10: Sales of major innovative cancer diagnosis (M $), 2006-08 113
Table 6.11: Beckman Coulter in R & D. (In million dollars) from 2004 to 08116
Table 6.12: the Bio-Rad sales ($ millions) 119 2004-2008
Table 6.13: Roche Diagnostics Division sales (CHF Million), 123 H109
Table 6.14: Major partnerships lately Dx-Rx 132

Please For more information contact:

http://www.aarkstore.com/reports/Innovations-in-Oncology-Diagnostics-Technological-advances-growth-opportunities-and-future-market-outlook-34066.html

About the Author

Minal H
SEO
vinod.minal@gmail.com
http://www.aarkstore.com




[mage lang="en|es|fr|en" source="answers"]hpv prostatitis[/mage]

Filed under: Prostate

Like this post? Subscribe to my RSS feed and get loads more!